Company Overview and News

KLCI gains after US equities' overnight rise

2018-10-17 theedgemarkets
KUALA LUMPUR (Oct 17): The FBM KLCI gained 3.75 points or 0.22% today with Asian shares after US equities' overnight rise.
HLFBF 3867 5819 1082 BATS 4162 2836 5246

FBM KLCI up 0.47% after Hong Leong Bank, MISC spike

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI gained 8.1 points or 0.47% to close at its intraday high after a sudden surge in the final trading hour. At a glance, the KLCI surged as prices of index-linked stocks Hong Leong Bank Bhd and MISC Bhd spiked.
3026 5819 2836

Bursa closes higher amid Asia rebound

2018-10-16 malaymail
KUALA LUMPUR, Oct 16 — Bursa Malaysia closed higher today, lifted by selective play in heavyweight counters, amid stronger regional markets.
GMALY 4715 GMALF 5819 BSMAF HIPEF 7066 1818 5199

Bursa higher at mid-afternoon

2018-10-16 malaymail
KUALA LUMPUR, Oct 16 — Bursa Malaysia continued higher at mid-afternoon today lifted by gains in selected index-linked companies, dealers said.
5819 5681 BSMAF HIPEF 7066 1818 5199

KLCI pares gains as sellers outpace buyers

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819

Strength of US markets rebound seen crucial

The US markets meltdown last week points to one danger ahead – the bursting of the margin debt stock bubble.

Bursa snaps seven-day losing streak

2018-10-12 malaymail
KUALA LUMPUR, Oct 12 — Bursa Malaysia snapped its seven-day losing streak to end higher today on renewed bargain hunting activity.
PBLOF 5819 7036 1295 BSMAF HIPEF 1818 5199

Bursa remains higher mid-afternoon

2018-10-12 malaymail
KUALA LUMPUR, Oct 12 — Bursa Malaysia continued its upward momentum at mid-afternoon, as the equity market gradually recovered from the recent two-day rout following the weak Wall Street performance overnight.
PBLOF 5819 1295 BSMAF HIPEF 1818 5199

KLCI up 0.79% in technical rebound, Maybank and TNB lift

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI rose 0.79% in a technical rebound at the midday break today, snapping its seven-day losing streak, lifted by index heavyweights including Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd (TNB).
HLFBF MLYBY MLYNF 7036 1082 7006 5135 6033 5199 CIMDF 1155 KLKBY 1023 2445 PNADF 5347 TNABY 6888 0006 5819 AXXTF TNABF HIPEF PNAGF

Bursa opens slightly lower

2018-10-12 malaymail
KUALA LUMPUR, Oct 12 — Bursa Malaysia was marginally lower at the opening today amid extended weaknesses in Wall Street’s performance overnight.
PBLOF 5819 7036 1295 BSMAF 3034 HIPEF 1818 5199

KLCI starts lower in line with frail regional markets

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI fell for the eighth day running this morning, amid frail regional sentiment.
HLFBF 3026 PBLOF 3867 5819 1082 1295 BSMAF 3034 7022 GBTKF 1818

Bursa plunges at opening in face of global weakness

2018-10-11 malaymail
KUALA LUMPUR, Oct 11 — Bursa Malaysia extended its losses at the opening today in line with Wall Street’s weaker performance overnight on concerns over global growth prospects.
PBLOF 5225 5819 7036 Q0F 1295 BSMAF IHHHF HIPEF 1818 5199

KLCI tumbles 2.63%, falls below 1,700-level

2018-10-11 theedgemarkets
KUALA LUMPUR (Oct 11): The FBM KLCI tumbled 2.63% in early trade this morning and slipped below the crucial 1,700-point threshold , tracking widespread losses at most regional markets.
KLKBY 2445 5347 3867 TNABY UPBMF 5819 BATS 4162 TNABF 2089 3719

Bursa ends sharply lower across the board

2018-10-10 malaymail
KUALA LUMPUR, Oct 10 — Share prices ended sharply lower across the board on Bursa Malaysia today due to a mix of local and external factors as investors, among others, cautiously digested government plans to introduce new taxes to reduce its debt obligation.
4863 PBLOF 5819 7036 MYTEF 1295 BSMAF HIPEF 1818 5199

Bursa Malaysia ends lower

2018-10-09 malaymail
KUALA LUMPUR, Oct 9 — Bursa Malaysia ended in the red today in line with the weaker performance in most regional markets on lack of positive catalysts, said a dealer.
PBLOF UPBMF BATS 4162 1295 2089 5256 5199 5225 5819 Q0F BSMAF IHHHF HIPEF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...